MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
MangoRx, a company specializing in men's health and wellness, has received a Notice of Allowance for its Japanese Patent Application No. 2021-545824. This patent, initially applied for by Intramont Technologies, covers a formulation designed to prevent oral and respiratory infections. The technology includes ingredients like GALALCOOL®️, zinc protoporphyrin IX, and tannins. This follows MangoRx's acquisition of Intramont's global patent portfolio, including U.S. Patent 11,517,523. The patent solidifies MangoRx's intellectual property and paves the way for introducing its products in Japan, aligning with its mission to offer advanced preventive care solutions.
- Received Notice of Allowance for Japanese Patent No. 2021-545824.
- Patent covers a new formulation for preventing oral and respiratory infections.
- Technology includes advanced ingredients like GALALCOOL®️, zinc protoporphyrin IX, and tannins.
- Follows the acquisition of Intramont Technologies' global patent portfolio.
- Also includes U.S. Patent 11,517,523, acquired on April 24, 2024.
- Strengthens intellectual property protection on a global scale.
- Enables entry into the Japanese market for preventive health products.
- No immediate financial gains or revenue figures cited from the patent allowance.
- Dependent on successful commercialization and market acceptance in Japan.
- Future profitability contingent on broader adoption and competitive positioning.
MangoRx's recent patent approval in Japan represents a meaningful milestone in its intellectual property strategy and potential revenue growth. The ability to protect and commercialize the preventive care technology in the Japanese market could open new revenue streams. Japan, being a significant market for health and wellness products, offers
The patent approval in Japan for MangoRx's preventive care technology could signify a breakthrough in the preventive health sector. The inclusion of unique ingredients like GALALCOOL®️, zinc protoporphyrin IX and select tannins places MangoRx in a strong position to offer innovative and comprehensive protection against oral and respiratory infections. This aligns with growing consumer demand for preventive health measures, particularly in markets with high health awareness such as Japan. However, competition in the preventive care market is fierce and MangoRx will need to execute effective marketing strategies to capture market share. Observing consumer adoption rates and market penetration in Japan will be key indicators of success.
The Notice of Allowance for MangoRx in Japan is a critical validation of the company's intellectual property, ensuring exclusive rights to their innovative formulation and application methods in a significant market. This legal protection is essential for safeguarding against potential infringements and maintaining a competitive edge. The acquisition of Intramont Technologies’ global patent portfolio further solidifies MangoRx's legal standing. Investors should remain aware of the potential for costly legal defenses and the need for ongoing patent renewals. The robustness of this IP portfolio could drive long-term value, making it a positive development for stakeholders.
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Allowance for Japanese Patent Application No. 2021-545824, originally applied for by Intramont Technologies, Inc. (“Intramont”).
This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies. The Notice of Allowance covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus (HPV). The US patent (Patent 11,517,523) was initially applied for by Intramont and subsequently acquired by MangoRx on April 24, 2024, further expanding the global protection for its groundbreaking preventive care technology.
Jacob Cohen, Co-Founder and CEO of MangoRx, expressed his enthusiasm about this achievement: “Receiving this Notice of Allowance in Japan is a critical step in our global strategy to protect and commercialize our innovative preventive care technology. It underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience. This patent not only fortifies our intellectual property but also paves the way for introducing our cutting-edge products to the Japanese market.”
The patented technology is designed to prevent illnesses acquired through the oral cavity and pharynx using an orally available solution, such as toothpaste, oral dissolvable tablets (ODT), lozenges, or mouthwash. The unique formulation features GALALCOOL®️, zinc protoporphyrin IX, and select tannins, which work synergistically to inhibit various pathogens, offering comprehensive protection against oral and respiratory infections.
This expansion aligns with MangoRx’s mission to enhance well-being through innovative health solutions. The Notice of Allowance in Japan joins an already robust portfolio of U.S. and international patents, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement; the Company’s stockholders’ equity as of the Company’s next fiscal quarter end; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock at
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
SOURCE: Mangoceuticals Inc.
![](https://ml.globenewswire.com/media/MDZkZWZiOTEtZjc5YS00OGE2LWFhMWQtMjc2MTAyNDQ4MGFjLTUwMDExNjEwNQ==/tiny/Mangoceuticals-Inc-.png)
FAQ
What is MangoRx's latest patent achievement?
What technology does MangoRx's new patent cover?
When did MangoRx acquire Intramont Technologies' global patent portfolio?
What ingredients are included in MangoRx's patented technology?
How does the new patent benefit MangoRx?